rosiglitazone has been researched along with metformin in 401 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.25) | 18.2507 |
| 2000's | 229 (57.11) | 29.6817 |
| 2010's | 153 (38.15) | 24.3611 |
| 2020's | 18 (4.49) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Botta, M; Brunetti, T; Cabri, W; Carminati, P; Corelli, F; Dottori, S; Giannessi, F; Pessotto, P; Prati, S; Rajamäki, S; Renzulli, M; Tassoni, E; Travagli, M | 1 |
| Washburn, WN | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bhatia, G; Kumar, A; Maurya, RA; Sharma, S; Srivastava, AK; Srivastava, SP; Tamrakar, AK; Tripathi, VD | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ahmad, P; Gupta, LP; Kumar, A; Rahuja, N; Sharma, S; Srivastava, AK; Srivastava, SP; Tamrakar, AK | 1 |
| Dwivedi, AK; Nath, C; Pratap, R; Raghubir, R; Satyanarayana, M; Singh, AB; Singh, H; Singh, SK; Srivastava, AK; Srivastava, M; Srivastava, SP; Tiwari, P; Verma, AK | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C | 1 |
| Haq, W; Katti, SB; Raza, S; Srivastava, AK; Srivastava, DS; Srivastava, SP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Fan, L; Li, Z; Ma, X; Tang, L; Wang, J; Wu, H; Xiao, W; Zhong, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kanojiya, S; Maurya, R; Mishra, A; Pandey, J; Patel, OP; Raju, KS; Saini, D; Shukla, SK; Srivastava, AK; Srivastava, MN; Tamrakar, AK; Taneja, I; Wahajuddin, M; Yadav, PP | 1 |
| Darvesh, AS; Geldenhuys, WJ; Leeper, TC; Morris, DL; Sullivan, PG; Yonutas, HM | 1 |
| Miao, J; Peng, JG; Tang, L; Wang, JT; Wang, ZX; Zhang, JQ; Zhang, Y; Zhou, XR | 1 |
| Kong, WJ; Li, YH; Niu, TY; Pang, YD; Song, DQ; Tang, S; Wang, C; Wang, YX; Zhang, YH | 1 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Fonseca, V; Patwardhan, R; Rosenstock, J; Salzman, A | 1 |
| Bakris, G | 1 |
| Allen, A; Carr, A; Di Cicco, RA; Fowles, S; Freed, MI; Jorkasky, DK | 1 |
| Bolesta, S; Malinowski, JM | 1 |
| Kenyon, CJ; Livingstone, DE; Walker, BR | 1 |
| Meneilly, GS; Tessier, D | 1 |
| Huijberts, MS; Sels, JP; Wolffenbuttel, BH | 1 |
| Berg, AH; Berger, J; Charron, MJ; Chatterjee, K; Combs, TP; Doebber, T; Gertz, BJ; Gottesdiener, KM; Larson, PJ; Moller, DE; O'Rahilly, S; Savage, DB; Scherer, PE; Tanen, M; Wagner, JA; Wang, WJ; Weiss, S; Zhang, BB | 1 |
| Khan, MA; St Peter, JV; Xue, JL | 1 |
| Freed, MI; Kreider, M; Lebovitz, HE | 1 |
| Carling, D; Fryer, LG; Parbu-Patel, A | 1 |
| Blickle, JF | 1 |
| Kiayias, JA; Lakka-Papadodima, E; Theodosopoulou, E; Vlachou, ED | 1 |
| Braddon, J; Phillips, P | 1 |
| Berry, RA; Freed, MI; Greene, DA; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Lachin, JM; Levy, D; Viberti, G; Zinman, B | 1 |
| Hällsten, K; Knuuti, J; Lönnqvist, F; Nuutila, P; Oksanen, A; Rönnemaa, T; Sipilä, H; Viikari, J; Viljanen, T; Virtanen, KA | 1 |
| Cleasby, ME; Livingstone, DE; Nyirenda, MJ; Seckl, JR; Walker, BR | 1 |
| Hällsten, K; Huupponen, R; Janatuinen, T; Knuuti, J; Lönnqvist, F; Lönnroth, P; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, T; Virtanen, KA | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF | 1 |
| Moses, R | 1 |
| Rochester, CD; Samuel, J | 1 |
| Ferrannini, E; Hallsten, K; Iozzo, P; Kemppainen, J; Knuuti, J; Lonnqvist, F; Nuutila, P; Oikonen, V; Parkkola, R; Solin, O; Virtanen, KA | 1 |
| Ballary, C; Desai, A | 1 |
| Bell, CF; Botteman, MF; Braunstein, SN; Devine, ST; Ramsdell, JW; Stephens, JM | 1 |
| Chen, J; Di, F; He, R; Wang, D; Wang, Y; Yang, J; Yang, M; Yuan, S; Zhu, X | 1 |
| Flight, IH; Lord, JM; Norman, RJ | 1 |
| Henry, RR | 1 |
| Evans, M; Rees, A; Roberts, AW; Thomas, A | 1 |
| Beck-Nielsen, H; Henriksen, JE; Hother-Nielsen, O; Poulsen, MK | 1 |
| Alarcon-Aguilar, FJ; Flores-Saenz, JL; Mendez-Francisco, JD; Rivas-Vilchis, JF; Roman-Ramos, R; Trujillo-Arriaga, HM | 1 |
| Cohen, SE; Kahn, CR; Michael, MD; Tseng, YH | 1 |
| Campbell, RK; Iltz, JL; Setter, SM; Thams, J | 1 |
| Bruce, S; Dailey, GE; Fiedorek, FT; Noor, MA; Park, JS | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Petersen, KU | 1 |
| Boyle, PJ; Buse, JB; Kendall, DM; Lau, H; Marchetti, A; Peters Harmel, AL | 1 |
| Bagool, MA; Deo, AA; Kolte, BL; Raut, BB; Shinde, DB | 1 |
| Althaym, A; Brunmair, B; Clara, R; Fürnsinn, C; Gnaiger, E; Gras, F; Nohl, H; Roden, M; Scharf, N; Staniek, K; Waldhäusl, W | 1 |
| Béréziat, V; Burnol, AF; Capitaine, N; Cariou, B; Girard, J; Kergoat, M; Laville, M; Le Marcis, V; Vega, N; Vidal, H | 1 |
| Bu, S; Chen, XP; Liu, XL; Wang, N; Xiao, JZ; Yang, WY; Zhao, WH | 1 |
| Baldeweg, S; Barbaro, D; Capaldo, B; Ferrannini, E; Gastaldelli, A; Natali, A; Toschi, E; Yudkin, JS | 1 |
| Del Prato, S; Volpe, L | 1 |
| Davidson, MB; Navar, M; Palomeno, G; Roy, R | 1 |
| Mikhail, N | 1 |
| Davidson, MB | 1 |
| Cleasby, ME; Cooney, GJ; Dzamko, N; Furler, SM; Hegarty, BD; Kraegen, EW; Ye, JM | 1 |
| Häkkinen, AM; Korsheninnikova, E; Mäkimattila, S; Nyman, T; Tiikkainen, M; Yki-Järvinen, H | 1 |
| Bell, DS; Ovalle, F | 1 |
| Mooradian, AD | 1 |
| Baillargeon, JP; Iuorno, MJ; Jakubowicz, DJ; Jakubowicz, S; Nestler, JE | 1 |
| Cox, SL | 1 |
| De, P | 1 |
| Hällsten, K; Janatuinen, T; Knuuti, J; Lehtimäki, T; Lönnqvist, F; Nuutila, P; Rönnemaa, T; Turiceanu, M; Viikari, J; Virtanen, KA | 1 |
| Aslan, E; Bagis, T; Erkanli, S; Haydardedeoglu, B; Kilicdag, EB; Tarim, E; Zeyneloglu, HB | 1 |
| Bayramiçli, OU; Gözü, H; Orbay, E; Sargin, H; Sargin, M; Yayla, A | 1 |
| Sauvanet, JP | 1 |
| Baldeweg, S; Baldi, S; Casolaro, A; Ferrannini, E; Natali, A; Sironi, AM; Toschi, E; Yudkin, JS | 1 |
| Fonseca, VA; Jawa, AA | 1 |
| Iyer, S; Perez, A; Rajagopalan, R | 1 |
| Cho, YM; Jung, HS; Kim, SY; Lee, HK; Park, HJ; Park, KS; Shin, CS; Youn, BS; Yu, KY | 1 |
| Hussein, MA; Perry, A; Vanderpoel, DR; Watson-Heidari, T | 1 |
| Björnholm, M; Chibalin, AV; Hällsten, K; Heinonen, OJ; Karlsson, HK; Lönnqvist, F; Nuutila, P; Tsuchida, H; Virtanen, KA; Zierath, JR | 1 |
| Al-Khalili, L; Forsgren, M; Kannisto, K; Krook, A; Lönnqvist, F; Zierath, JR | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S | 1 |
| Schumm-Draeger, PM | 1 |
| James, AP; Mamo, JC; Watts, GF | 1 |
| Carr, DB; Hull, RL; Kahn, SE; Kodama, K; Shen, ZP; Utzschneider, KM; Wang, F; Watts, MR; Zraika, S | 1 |
| Moreno Sánchez, D | 1 |
| Beck-Nielsen, H; Biswas, N; Dargie, H; Gomis, R; Gubb, J; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; Pocock, SJ | 1 |
| Wellington, K | 1 |
| Hirosumi, J; Ita, M; Kawamura, I; Mabuchi, M; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S; Yamamoto, T | 1 |
| Whitelaw, D | 1 |
| Arslan, M; Ayvaz, G; Bukan, N; Cakir, N; Karakoç, A; Törüner, F; Yilmaz, M | 1 |
| Bell, DS; Vaughan, TB | 1 |
| Dazzi, D; Hassan, H; Mangieri, T; Negro, R; Pezzarossa, A | 1 |
| Bauer, MF; Francesconi, C; Hohenecker, J; Ledl, M; Roden, M; Roots, I | 1 |
| Cabezas, MC; de Koning, EJ; Hoepelman, AI; Joven, J; op't Roodt, J; Rabelink, TJ; van Wijk, JP | 1 |
| Dehmel, B; Petzoldt, R; Reblin, T; Rosak, C; Seidel, D; Wolf, R | 1 |
| Ferrannini, E; Hällsten, K; Iozzo, P; Järvisalo, MJ; Lönnqvist, F; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, AP; Virtanen, KA | 1 |
| Janez, A; Karner, P; Maticic, M; Sharma, PM; Tomazic, J; Vidmar, L | 1 |
| Abdel-Salam, OM; Baiuomy, AR; El-Batran, SA; Nofal, SM | 1 |
| Andrew, R; Livingstone, DE; McInnes, KJ; Walker, BR | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S | 1 |
| Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J | 1 |
| Bagdonas, A; Bailey, CJ; Biswas, N; Donaldson, J; McMorn, SO; Rubes, J; Stewart, MW | 1 |
| Arslan, M; Ayvaz, G; Cakir, N; Karakoç, A; Tiras, B; Törüner, FB; Yilmaz, M | 1 |
| Mitkov, M; Pehlivanov, B; Terzieva, D | 1 |
| Donnelly, R; Rea, R | 1 |
| Cobitz, AR; Goldstein, BJ; Rosenstock, J; Strow, LJ; Waterhouse, B; Weissman, P; Wooddell, MJ | 1 |
| Cobitz, AR; Freed, MI; Rood, JA; Ryan, CM; Strachan, MW; Waterhouse, BR | 1 |
| Bruce, S; Garber, A; Klein, E; Mohideen, P; Sankoh, S | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Gaddi, AV; Ghelfi, M; Piccinni, MN; Salvadeo, S | 1 |
| Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M | 1 |
| Campbell, SC; Macfarlane, WM; Richardson, H; Smith, SA | 1 |
| Dailey, G; Rosenstock, J; Soltes-Rak, E; Stewart, JA; Strange, P; Sugimoto, D | 1 |
| Esposito, K; Giugliano, D | 1 |
| Das, S; Maji, D; Roy, RU | 1 |
| Ardawi, MS; Rouzi, AA | 1 |
| Andreelli, F; Beauloye, C; Bertrand, L; Foretz, M; Guigas, B; Horman, S; Taleux, N; Viollet, B | 1 |
| Boscaro, M; Grossman, AB; Kola, B; Korbonits, M; Rutter, GA | 1 |
| Smits, P; Tack, CJ | 1 |
| Chen, WK; Wang, T; Zhang, DM; Zhang, GY; Zhong, HJ | 1 |
| Bagust, A; Beale, S; Hulme, L; Martin, A; Shearer, AT | 1 |
| Bagust, A; Goertz, A; Liebl, A; Schoeffski, O; Shearer, AT | 1 |
| Ampudia-Blasco, FJ; Bagust, A; Martínez-Lage Alvarez, B; París, G; Pérez Escolano, I; Shearer, AT | 1 |
| Alonso-Villaverde, C; Camps, J; Castro Cabezas, M; Coll, B; de Koning, EJ; Ferre, N; Hoepelman, IM; Joven, J; Parra, S; Rabelink, TJ; Tous, M; van Wijk, JP | 1 |
| Almoznino-Sarafian, D; Alon, I; Berman, S; Cohen, N; Efrati, S; Gorelik, O; Shteinshnaider, M; Weissgarten, J | 1 |
| Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA | 2 |
| Bradley, JD; Geary, RS; Kwon, Y; van Lier, JJ; VanVliet, AA; Watanabe, T; Wedel, M | 1 |
| Gerstein, HC; Hanley, AJ; Harris, SB; Neuman, J; Raboud, JM; Young, TK; Zinman, B | 1 |
| Bakris, GL; Freed, MI; Heise, MA; McMorn, SO; Porter, LE; Ruilope, LM; Weston, WM | 1 |
| Cobitz, AR; Goldstein, BJ; Waterhouse, BR; Weissman, PN; Wooddell, MJ | 1 |
| Biswas, N; Cirkel, DT; Donaldson, J; Furuseth, K; Hamann, A; Phenekos, C; Starkie, MG; Stewart, MW | 1 |
| Elhadd, TA; Fiad, T; Meer, L | 1 |
| Hamid, Z; Simmons, DL | 1 |
| Biswas, N; Chou, H; Cobitz, A; Garber, A; Rood, J; Rosenstock, J | 1 |
| Bellot-Rojas, P; Caracas-Portilla, N; Cardoso-Saldaña, G; Jurado-Santacruz, F; Posadas-Romero, C; Posadas-Sanchez, R; Zamora-Gonzalez, J | 1 |
| Cersosimo, E; De Filippis, E; DeFronzo, RA; Gastaldelli, A; Glass, L; Miyazaki, Y; Triplitt, C; Wajcberg, E | 1 |
| Freed, MI; Haffner, S; Heise, MA; Herman, WH; Holman, R; Jones, NP; Kahn, SE; Kravitz, B; Lachin, J; O'Neill, MC; Viberti, G; Zinman, B | 1 |
| Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Kravitz, BG; Lachin, JM; O'Neill, MC; Viberti, G; Zinman, B | 1 |
| Nathan, DM | 2 |
| Eriksson, P; Fisher, RM; Hamsten, A; Kannisto, K; Kolak, M; Tiikkainen, M; Yki-Järvinen, H | 1 |
| Alston-Smith, BL; Basar, MT; Fielding, RA; Grinspoon, S; Koletar, SL; Mulligan, K; Parker, RA; Schouten, JT; Wininger, DA; Yang, Y | 1 |
| Bottomley, J; Diamantopoulos, A; Mariz, S; O'Bryan-Tear, G; Tilden, DP | 1 |
| Allemann, S; Braun, M; Chappuis, B; Christ, ER; Diem, P; James, R; Lumb, PJ; Stettler, C; Wierzbicki, AS | 1 |
| Ahn, CW; Cha, BS; Chung, CH; Kang, ES; Kim, DJ; Kim, HJ; Kim, SH; Lee, HC; Lee, KW; Nam, CM; Nam, M | 1 |
| Jezior, MR; Langley, RW; Stocker, DJ; Taylor, AJ; Vigersky, RA | 1 |
| Scheen, AJ | 1 |
| Brunani, A; Castagna, G; Caumo, A; Graci, S; Liuzzi, A; Viberti, G | 1 |
| Kanna, B; Pokharna, H | 1 |
| Garg, R | 1 |
| Demers, LM; Dodson, WC; Gnatuk, CL; Kunselman, AR; Legro, RS; Williams, NI; Zaino, RJ | 1 |
| Aksoy, N; Akyüz, F; Beşişik, F; Boztaş, G; Cakaloğlu, Y; Cevikbaş, U; Demir, K; Ibrişim, D; Kaymakoğlu, S; Mungan, Z; Okten, A; Ozdil, S; Poturoğlu, S | 1 |
| Elo, B; Govorko, D; Villano, CM; White, LA | 1 |
| Epstein, L; Grey, M; Hirst, K; Kaufman, F; Tamborlane, W; Wilfley, D; Zeitler, P | 1 |
| Chen, Y; Tian, Y; Zhang, L; Zhang, Z | 1 |
| Goldberg, RA; Lee, S; McCann, JD; Tsirbas, A | 1 |
| Atanasova, I; Genchev, G; Kamenov, Z; Khristov, V; Kolarov, G; Milcheva, B; Orbetsova, M; Shigarminova, R; Zakharieva, S | 1 |
| Hitch, WJ; Jackson, VL; Scott, MA | 1 |
| Beck-Nielsen, H; Curtis, P; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; Pocock, SJ | 1 |
| Beck-Nielsen, H; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ | 1 |
| Koro, C; Landon, J; McAfee, AT; Walker, AM; Ziyadeh, N | 1 |
| Smiley, D; Umpierrez, G | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Piccinni, MN; Pricolo, F; Salvadeo, SA | 1 |
| Garber, A | 1 |
| Einecke, D | 1 |
| Bussel, II; Felgner, J; Jafari, M; Khodayari, B; Mueller, LD; Rose, MR | 1 |
| Jacob, S | 1 |
| Matthaei, S | 1 |
| Hanefeld, M | 1 |
| Bilous, RW | 1 |
| Gursoy, A; Guvener Demirag, N; Sahin, M; Yilmaz, H | 1 |
| Bahtiyar, G; Sacerdote, AS; Weiss, K | 1 |
| Elasy, T; Stafford, JM | 1 |
| Atkinson, LL; Benkoczi, C; Finegood, DT; McDonald-Dyck, C | 1 |
| Chalasani, N; Khashab, M | 1 |
| Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S | 1 |
| Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM | 1 |
| Deeks, ED; Keam, SJ | 1 |
| Javashvili, L; Kilasonia, L; Tananashvili, D; Tetradze, L; Virsaladze, D | 1 |
| Bahia, LR; Bottino, DA; Bouskela, E; Kraemer de Aguiar, LG; Nivoit, P; Villela, NR | 1 |
| Janez, A; Karner, P; Maticic, M; Sharma, P; Silic, A; Tomazic, J; Vidmar, L | 1 |
| Bailey, MF; Castelli, LA; Iseli, TJ; Katsis, F; Kemp, BE; Macaulay, SL; Michell, BJ; Oakhill, JS; Stapleton, D; van Denderen, BJ; Walter, M; Wee, S; Witters, LA | 1 |
| Atkin, SL; Cho, LW | 1 |
| Donaldson, J; Garcia-Puig, J; Hamann, A; Paul, G; Stewart, M | 1 |
| Demidova, TIu; Erokhina, EN | 1 |
| Alagona, C; Chiavetta, A; Fedele, V; Leotta, C; Lorenti, I; Luca, S; Papa, G; Pezzino, V; Piro, S; Purrello, F; Rabuazzo, AM; Spadaro, L | 1 |
| Davies, MJ; Engel, SS; Loeys, T; Scott, R | 1 |
| Chou, HS; Hamann, A; Matthaei, S; Rosenstock, J; Seidel, DK | 1 |
| Aftring, RP; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Viberti, G; Yu, D; Zinman, B | 1 |
| Dachs, R; Darby-Stewart, A; Graber, MA | 1 |
| Glueck, C; Goldenberg, N | 1 |
| Bachmakov, I; Fromm, MF; Glaeser, H; König, J | 1 |
| Janez, A; Jensterle, M; Marc, J; Mlinar, B; Pfeifer, M; Prezelj, J | 1 |
| Costa, B | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA | 1 |
| Koro, CE; Landon, J; Walker, AM | 1 |
| Chaikledkeaw, U; Chaiyakunapruk, N; Chirakup, S; Ongphiphadhanakul, B; Palmer, AJ; Pongcharoensuk, P; Roze, S; Valentine, WJ | 1 |
| Atabek, ME | 1 |
| Alemao, E; Chen, J; Cook, J; Yin, D | 1 |
| Alemao, E; Chen, J; Cook, J; Gouveia, M; Jameson, K; Krishnarajah, G; Nocea, G; Schwarz, B; Sintonen, H; Yin, D | 1 |
| Beck-Nielsen, H; Curtis, P; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; Pocock, SJ; Zambanini, A | 1 |
| Bektas, M; Coban, S; Corapcioglu, D; Doganay, B; Emral, R; Erden, E; Idilman, R; Mizrak, D; Ozden, A; Sayki, M; Soykan, I; Uysal, AR | 1 |
| Benavides, S; Romo, A | 1 |
| Colette, C; Monnier, L; Owens, DR | 1 |
| Hamilton, JK; Hanley, AJ; Retnakaran, R; Shen, S; Vuksan, V; Zinman, B | 1 |
| Farah, R; Lapin, O; Shurtz-Swirski, R | 1 |
| Janez, A; Jensterle, M; Keber, I; Kocjan, T; Pfeifer, M; Prezelj, J; Sebestjen, M | 1 |
| Hu, M; Luo, Y; Tian, H; Wu, W; Zhang, H; Zhou, X | 1 |
| Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A | 1 |
| Braga, MB; Gupta, M; Verma, S | 1 |
| Diamant, M; Scheffer, PG; Schumm-Draeger, PM; Siegmund, T; von Bibra, H | 1 |
| Chalasani, N; Vuppalanchi, R | 1 |
| Abraira, C; Davis, SN; Duckworth, W; Emanuele, N; Goldman, S; Hayward, R; Henderson, WG; Huang, GD; Marks, J; McCarren, M; Moritz, T; Reaven, PD; Reda, D; Vitek, ME; Warren, SR; Zieve, FJ | 1 |
| Balabolkin, MI; Klebanova, EM; Kreminskaia, VM; Kuzin, AG; Mamaeva, GG; Tel'nova, ME | 1 |
| Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS | 1 |
| Bloomgarden, ZT | 1 |
| Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL | 1 |
| Lewin, A; Lyness, W; Raskin, P; Reinhardt, R | 1 |
| Akinci, B; Bayraktar, F; Comlekci, A; Demir, T; Ozcan, MA; Yener, S; Yesil, S; Yuksel, F | 1 |
| Retnakaran, R; Zinman, B | 1 |
| Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ | 1 |
| Carpinteri, R; Doga, M; Giustina, A; Mancini, T; Mazziotti, G; Simetovic, N; Vescovi, PP | 1 |
| Li, K; Li, L; Liu, H; Yang, G; Yang, M; Zong, H | 1 |
| Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM | 1 |
| Abdel-Gaber, SA; Ashour, OM; Fouad, AA; Morsy, MA | 1 |
| Chen, PF; Hsiao, FY; Huang, WF; Kuo, KN; Tsai, YW; Wen, YW | 1 |
| Arnol, V; Cortizo, AM; Gangoiti, MV; McCarthy, AD; Molinuevo, MS; Schurman, L; Sedlinsky, C; Tolosa, MJ | 1 |
| Choe, C; Christiansen, L; Ciaraldi, TP; Henry, RR; Kung, J; Mudaliar, S; Phillips, SA | 1 |
| Akarca, U; Akyildiz, M; Batur, Y; Cetinkalp, S; Omer, Z; Yilmaz, C; Yilmaz, F | 1 |
| Baran, I; Budak, F; Duran, C; Ersoy, C; Erturk, E; Fazlioglu, M; Gul, OO; Imamoglu, S; Kaderli, A; Kiyici, S; Sigirli, D; Tuncel, E | 1 |
| Bao, Y; Jia, W; Qiu, Y; Su, M; Wang, X; Zhao, T | 1 |
| McGill, JB | 1 |
| Derosa, G; Maffioli, P; Tinelli, C | 1 |
| Onal, A | 1 |
| Jiang, JD; Kong, WJ; Pan, HN; Song, DQ; Wang, SK; Wang, YM; Wang, ZZ; Wei, J; Wu, JD; Xue, R; Zhang, H; Zhao, W; Zhou, ZX | 1 |
| Finck, BN; Gropler, RJ; Herrero, P; Schechtman, KB; Sharp, T; Shoghi, KI; Welch, MJ | 1 |
| Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Yu, D; Zinman, B | 1 |
| Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Liapis, CD; Sailer, N; Tsanikidis, H; Vitta, I; Vrabas, I | 1 |
| Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B | 1 |
| Argo, TR; Housel, AK; Waterbury, N | 1 |
| Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR | 1 |
| DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C | 1 |
| Ahmed, MS; Hankins, GD; Hemauer, SJ; Nanovskaya, TN; Patrikeeva, SL | 1 |
| Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC | 1 |
| Dushinat, M; Friedman, N; Halkin, H; Katzir, I; Kokia, E; Kurnik, D; Loebstein, R; Lomnicky, Y; Silverman, B; Vesterman-Landes, J | 1 |
| Agra, R; Albuquerque, JL; Arahata, C; Arruda, MJ; Canadas, V; Gusmão, A; Montenegro, L; Pontes, L; Silva, LM; Vilar, CF; Vilar, L | 1 |
| Beck-Nielsen, H; Home, PD; Jones, NP; Kahn, SE; Noronha, D; Viberti, G | 1 |
| Larson, RJ; Sheth, SH | 1 |
| Gerstein, HC; Hanley, AJ; Harris, SB; Neuman, J; Qi, Y; Raboud, J; Retnakaran, RR; Zinman, B | 1 |
| Buchanan, TA; Xiang, AH | 1 |
| Chen, YT; Cheng, JT; Chi, TC; Lee, HH; Lo, SH; Yeh, CH | 1 |
| Chen, L; Wu, Z; Zhao, XM | 1 |
| Banerjee, A; Flynt, L; Ghosh, S; Mellema, M; Panettieri, RA; Shore, SA; Williams, E; Zhu, M | 1 |
| Beck-Nielsen, H; Christiansen, C; Gjessing, H; Gram, J; Grodum, E; Hangaard, J; Hansen, HM; Hansen, TB; Henriksen, JE; Juhl, H; Vestergaard, V; Yderstræde, K | 1 |
| Cabezas, MC; Dallinga-Thie, G; de Koning, EJ; Hoepelman, AI; Rabelink, TJ; van Wijk, JP | 1 |
| Corrada, E; Ferrante, G; Presbitero, P; Zavalloni, D | 1 |
| Malaga, G; Miranda, JJ | 1 |
| Casazza, G; Ceriani, E; Costantino, G; Podda, GM | 1 |
| Al-Jebawi, AF | 1 |
| Kadoglou, NP; Kapelouzou, A; Liapis, CD; Sailer, N; Tsanikidis, H; Vitta, I | 1 |
| Gerstein, HC; Hettinga, BP; Holloway, AC | 1 |
| Li, XJ; Liu, CQ; Wang, LY; Yan, B; Yang, SY; Yu, YX; Zhang, HJ; Zhang, SH; Zhang, W | 1 |
| Bashir, M; Idrees, M; Khan, RU; Malik, SA; Rahman, IU | 1 |
| Chen, L; Ma, A; Shen, M; Zhou, Z | 1 |
| Cross, JT; Gardner, JS; Garrison, LP; Veenstra, DL | 1 |
| Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B | 2 |
| Erem, C; Fidan, E; Karahan, C; Kocak, M; Onder Ersoz, H; Yilmaz, H; Yilmaz, M | 1 |
| Maier, V; Ranc, V; Ševčík, J; Znaleziona, J | 1 |
| Dong, JJ; Liao, L; Tian, YJ; Xin, Y; Xing, HY; Zhao, JJ | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Li, D; Li, X; Li, Y; Ming, J; Shi, Y; Xie, Y; Zhang, N | 1 |
| Kim, CM; Lee, DH; McGuire, M; Suh, DC | 1 |
| Crabb, DW; Liangpunsakul, S; Lu, C; Sozio, MS; Zeng, Y | 1 |
| Hanley, AJ; Harris, SB; Qi, Y; Retnakaran, R; Zinman, B | 1 |
| Kahn, SE; Utzschneider, KM | 1 |
| Harrison, SA; Jones, FJ; Shaw, JC; Torres, DM; Ward, JA; Williams, CD | 1 |
| Heller, C; Kühn, MC; Mülders-Opgenoorth, B; Scherbaum, WA; Schinner, S; Schott, M; Willenberg, HS | 1 |
| Li, L; Liu, H; Yang, G; Yang, M; Zhang, L | 1 |
| Cortizo, AM; Felice, JI; McCarthy, AD; Molinuevo, MS; Sbaraglini, ML; Schurman, L; Sedlinsky, C; Tolosa, MJ | 1 |
| Barboza, J; Sando, KR; Taylor, J; Willis, C | 1 |
| Awasthi, S; Nagaprashantha, L; Singhal, J; Singhal, SS; Vatsyayan, R | 1 |
| Chalasani, N; Corey, KE | 1 |
| Gadzhanova, S; Gillies, M; Roughead, E; Zuo, Y | 1 |
| Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N | 1 |
| Chaudhuri, A; Dandona, P; DiGenio, A; Hollander, P; Ilgenfritz, J; McGill, JB; Meneghini, L; Riddle, M; Rosenstock, J | 1 |
| Bado, A; Barraud, C; Boschat, L; Buyse, M; Farinotti, R; Hindlet, P | 1 |
| Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP | 1 |
| Doubova, SV; Flores-Hernández, S; Mino-León, D; Reyes-Morales, H | 1 |
| Abd el-Latif, FF; Khalifa, M; Sayed, AA | 1 |
| Greevy, RA; Griffin, MR; Grijalva, CG; Hung, AM; Ikizler, TA; Liu, X; Murff, HJ; Roumie, CL | 1 |
| Aimaretti, G; Cittadini, A; Isgaard, J; Longobardi, S; Monti, MG; Napoli, R; Netti, PA; Rea, D; Saccà, L; Samà, M; Walser, M | 1 |
| Nauck, MA | 1 |
| Pan, D; Pan, LF; Teng, BS; Wang, CD; Wu, JS; Yang, HJ; Zhang, D; Zhou, P | 1 |
| Arslanian, S; Copeland, K; Cuttler, L; Hirst, K; Kaufman, F; Linder, B; Nathan, DM; Pyle, L; Tollefsen, S; Wilfley, D; Zeitler, P | 1 |
| Allen, DB | 1 |
| Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L | 1 |
| Home, P | 1 |
| Andreeff, M; Benito, JM; Chen, C; Fuentes-Mattei, E; Jin, Y; Konopleva, M; Lee, MH; Pan, J; Velazquez-Tores, G; Yeung, SC | 1 |
| Amatruda, JM; Aschner, P; Chen, Y; Dobs, AS; Duran, L; Ferreira, JC; Goldstein, BJ; Golm, GT; Hill, JS; Horton, ES; Kaufman, KD; Langdon, RB; Umpierrez, GE; Williams-Herman, DE | 1 |
| Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D | 1 |
| Atar, D; Serebruany, VL | 1 |
| Chen, SG; Cheng, XY; He, JW; Li, H; Lu, ML; Qu, S; Sheng, CJ; Wang, C; Wang, KS; Yu, YC | 1 |
| Choi, MG; Jung, JS; Kang, YJ; Kim, CH; Kim, SJ; Kim, SS; Park, SH; Ryu, OH; Sim, YB; Suh, HW | 1 |
| Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME | 1 |
| Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC | 1 |
| Cloix, L; Cornuau, M; Dupont, J; Guerif, F; Ramé, C; Reverchon, M; Royère, D | 1 |
| Beydoun, H; Beydoun, M; Kancherla, V; Stadtmauer, L | 1 |
| Dyer, C | 1 |
| Alexandraki, KI; Apostolopoulos, NV; Berry, R; Jude, EB; Mohiyiddeen, L; Watson, AJ | 1 |
| Bilezikian, JP; Cobitz, AR; Eastell, R; Fitzpatrick, LA; Josse, RG; Kravitz, BG; Lewiecki, EM; Miller, CG; Nino, AJ; Northcutt, AR; Paul, G; Wooddell, M | 1 |
| Bahn, G; Koska, J; Reaven, PD; Saremi, A; Yamashita, S | 1 |
| Boyko, EJ; Floyd, JS; Forsberg, CW; Moore, K; Riley, K; Smith, NL; Wheeler, S | 1 |
| Atamer, A; Atamer, Y; Can, AS; Hekimoğlu, A; Ilhan, N; Koçyiğit, Y; Yenice, N | 1 |
| Al-Daghri, NM; Al-Othman, A; Al-Saleh, Y; Alkharfy, KM; Alokail, MS; Chrousos, GP; Kumar, S; Moharram, O; Sabico, SB | 1 |
| Chen, A; Deng, W; Fang, D; Huang, Z; Li, H; Li, Y; Liu, J; Liu, L; Wan, X; Wei, G | 1 |
| Burcelin, R; Fernández-Real, JM; Frühbeck, G; Luche, E; Mayas, D; Mingrone, G; Moreno-Navarrete, JM; Ortega, FJ; Ricart, W; Rodriguez-Hermosa, JI; Serino, M; Tinahones, FJ | 1 |
| Huang, L; Weng, C; Xing, X; Yang, Y; Yuan, H | 1 |
| Argraves, WS; Cangemi, C; Christensen, MM; Gram, J; Grodum, E; Henriksen, JE; Rasmussen, LM; Skov, V; Sørensen, D | 1 |
| Asiri, Y; Barr, AM; Boyda, HN; Honer, WG; Lo, R; Pang, CC; Procyshyn, RM; Wang, CK; Wu, C | 1 |
| Anthony, J; Bhumra, SK; Deka, N; Kelkar, A; Marita, AR; Mutt, S; Mutt, SJ; Ranjith, V; Sharma, S; Sivaramakrishnan, H; Wilankar, C | 1 |
| Hofer, A; Kladt, N; Lellek, V; Noe, N; Schauß, A; Tischner, C; Wenz, T | 1 |
| Chen, J; Hahn, SS; Tang, Q; Wu, J; Zhao, S; Zheng, F | 1 |
| Bland, JS; Darland, G; Desai, A; Grayson, N; Konda, VR | 1 |
| Emoto, M; Fukumoto, S; Imanishi, Y; Inaba, M; Ishimura, E; Koyama, H; Mori, K; Morioka, T; Motoyama, K; Nakatani, S; Ochi, A | 1 |
| Balakrishnan, P; Bass, E; Bennett, WL; Bolen, S; Clark, JM; Gribble, MO; Kao, WH; Maruthur, NM; Sahu, A; Wilson, LM | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Arnett, TR; Butters, OR; Patel, JJ | 1 |
| Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK | 1 |
| Bertoldo, MJ; Dupont, J; Froment, P; Ramé, C; Reverchon, M | 1 |
| Narasimhan, S; Weinstock, RS | 1 |
| Chevalier, S; Farsijani, S | 1 |
| Agarwal, S; Bilezikian, JP; Fitzpatrick, LA; Manavalan, JS; McMahon, DJ; Nino, A; Rubin, MR | 1 |
| Breunig, IM; McPherson, ML; Shaya, FT; Snitker, S | 1 |
| Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Isozaki, Y; Maruyama, T; Matsubara, H; Mori, M; Murakami, K; Nakayama, T; Nishimori, T; Suito, H; Suzuki, A; Takahashi, M; Takeshita, N; Toyozumi, T | 1 |
| Prasad, V | 1 |
| Li, YX; Sun, Q; Zeng, JB; Zhang, Y | 1 |
| Ben-Hander, GM; Cheng, KW; Makahleh, A; Saad, B; Saleh, MI | 1 |
| Herrigel, DJ; Moss, RA | 1 |
| Chai, Z; Li, L; Liu, C; Shen, X; Wang, L; Zhang, X; Zhang, Z | 1 |
| Curtis, PS; Home, PD; Jones, NP | 1 |
| Ciaraldi, TP; Samad, F; Wang, J | 1 |
| Abi Salloum, B; Beckett, E; Herkimer, C; Moeller, J; Padmanabhan, V; Sreedharan, R; Veiga-Lopez, A | 1 |
| Doblhammer, G; Fink, A; Heneka, MT | 1 |
| Peuler, JD; Phelps, LE | 1 |
| Calingaert, B; Margulis, AV; Perez-Gutthann, S; Pladevall, M; Riera-Guardia, N; Varas-Lorenzo, C | 1 |
| Bhatnagar, A; Conklin, DJ; Haberzettl, P; McCracken, JP | 1 |
| Adams, LA; Bedwell, DW; Calvert, NA; Cassidy, KC; Cramer, JW; Mohutsky, MA; Moulton, RD; Rougée, LR; Ruterbories, KJ; Yumibe, NP; Zhou, X | 1 |
| Dong, Z; Duan, H; Ji, X; Jiang, P; Li, M; Li, X; Ma, B; Ma, X; Ni, Z; Wang, B; Wei, Q | 1 |
| Chen, YT; Liu, YM; Ou, HT; Wu, JS | 1 |
| Gandica, R; Zeitler, P | 1 |
| Bucher, KG; Wiltz, SA | 1 |
| Areosa Sastre, A; González-Colaço Harmand, M; Martínez, G; Vernooij, RW | 1 |
| Akkoc, H; Akkus, M; Kelle, I; Topal, AE; Yilmaz, S | 1 |
| Kang, DR; Kim, DJ; Lee, KJ; Lee, S; Noh, Y; Shin, S | 1 |
| Andersson, AD; Enerbäck, S; Eriksson, O; Faxius, L; Gomez, MF; Guiducci, L; Hällsten, K; Heglind, M; Iozzo, P; Kauhanen, SP; Koffert, JP; Mikkola, K; Nuutila, P; Parkkola, R; Pham, T; Saraste, A; Silvola, JMU; Virta, J; Virtanen, KA | 1 |
| Choe, C; Ciaraldi, TP; Farr, O; Henry, RR; Hwang, WM; Kang, MC; Kim, SS; Kim, YB; Lim, DM; Mantzoros, C; Park, KS; Seo, JA | 1 |
| Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
| Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E | 1 |
| Bacha, F; Bjornstad, P; El Ghormli, L; Gidding, SS; Levitsky, LL; Levitt Katz, LE; Lima, JAC; Lynch, J; Tryggestad, JB; Weinstock, RS | 1 |
| Gao, H; Hong, T; Wang, H; Wei, R; Yang, J; Yu, F | 1 |
| Beck-Nielsen, H; Brøsen, K; Christensen, MH; Frost, M; Gram, J; Jørgensen, NR; Stage, TB | 1 |
| Arslanian, SA; Braffett, BH; Caprio, S; Geffner, ME; Kelsey, MM; Levitsky, LL; McKay, SV; Shah, R; Sprague, JE | 1 |
| Liu, X; Xu, W; Zeng, L | 1 |
| Chang, CH; Chen, PC; Chuang, LM; Dong, YH; Ko, WC; Wang, JL; Wu, LC | 1 |
| Chen, SH; Liu, XN; Peng, Y; Sun, QY | 1 |
| Craig, A; Issberner, J; Parvez, F | 1 |
| Bennett, PH; Crandall, JP; Edelstein, SL; Goldberg, RB; Kahn, SE; Knowler, WC; Mather, KJ; Mudaliar, S; Nathan, DM; Orchard, TJ; Temprosa, M; White, NH | 1 |
| Bhat, D; Butt, TP; Choh, N; Ganie, MA; Gupta, N; Masoodi, SR; Nisar, S; Rashid, A; Sofi, NY; Sood, M; Wani, IA | 1 |
| Duan, C; Hu, Y; Huang, W; Li, Y; Tan, J; Wang, Q | 1 |
| Blazina, I; Selph, S | 1 |
| Arya, S; Hansen, KR; Wild, RA | 1 |
| Arslanian, S; Chan, CL; Chernausek, SD; El Ghormli, L; Gandica, RG; Gubitosi-Klug, R; Haymond, MH; Levitsky, LL; Siska, M; Willi, SM | 1 |
| Abbulu, K; Bhende, SD; Varanasi, MB | 1 |
| Bacha, F; Braffett, BH; Gidding, SS; Gubitosi-Klug, RA; Levitt Katz, LE; Shah, AS; Shah, RD; Tryggestad, JB; Urbina, EM | 1 |
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| Chandran, A; Drews, K; El Ghormli, L; Sylvetsky, AC; Talegawkar, SA; Welsh, JA | 1 |
| Chi, CC; Lee, CY; Liu, CY; Tien O'Donnell, F; Tung, TH; Wang, SH | 1 |
| Augustin, S; Beguier, F; Berrod, JP; Blot, G; Charles-Messance, H; Conart, JB; Delarasse, C; Guillonneau, X; Léveillard, T; Millet-Puel, G; Roubeix, C; Sahel, JA; Sennlaub, F; Touhami, S | 1 |
| Kelsey, MM; Pyle, L | 1 |
| Flatt, PR; Moffett, RC; Sarnobat, D; Tarasov, AI | 1 |
| Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N | 2 |
| Ali, R; Allison, BA; Baker, C; Jonas, DE; LeBlanc, ES; Middleton, JC; Riley, S; Vander Schaaf, EB; Voisin, CE | 1 |
| Alqahtani, F; Cruz-Topete, D; Cucullo, L; Dhaibar, H; Sivandzade, F | 1 |
66 review(s) available for rosiglitazone and metformin
| Article | Year |
|---|---|
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.
Topics: Aged; Area Under Curve; Biological Availability; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Diabetes in elderly adults.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diet Therapy; Exercise; Female; Glyburide; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2001 |
Rosiglitazone.
Topics: Animals; Blood Pressure; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
[Rosiglitazone: clinical data].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
Oral hypoglycaemics. When not to use what.
Topics: Acarbose; Acidosis, Lactic; Aged; Contraindications; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Renal Insufficiency; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Metformin; Middle Aged; Obesity; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Combination agents for diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2003 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2003 |
Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
Topics: Clinical Trials as Topic; Contraindications; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2004 |
Towards single-tablet therapy for type 2 diabetes mellitus. Rationale and recent developments.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2004 |
Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
Topics: Angioplasty, Balloon, Coronary; Animals; Biguanides; Blood Pressure; Chromans; Diabetic Angiopathies; Endothelium, Vascular; Fibrinolysis; Humans; Hypoglycemic Agents; Metformin; Oxidative Stress; Postprandial Period; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Troglitazone | 2005 |
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Rosiglitazone/Metformin.
Topics: Animals; Diabetes Mellitus; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Therapeutic Equivalency; Thiazolidinediones | 2005 |
[Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases].
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adipogenesis; Allosteric Regulation; AMP-Activated Protein Kinases; Animals; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Design; Energy Intake; Energy Metabolism; Enzyme Activation; Fatty Acids; Glucose; Homeostasis; Humans; Hypothalamus; Lipogenesis; Mammals; Metformin; Models, Biological; Multienzyme Complexes; Myocardium; Obesity; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Subunits; Rosiglitazone; Thiazolidinediones | 2006 |
Expanding role of AMPK in endocrinology.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Appetite Regulation; Cannabinoids; Cytokines; Endocrine System; Fatty Acid Synthases; Ghrelin; Glucose; Humans; Hypothalamic Hormones; Insulin; Leptin; Metformin; Models, Biological; Multienzyme Complexes; Peptide Hormones; Protein Serine-Threonine Kinases; Receptors, Adrenergic; Resistin; Rosiglitazone; Thiazolidinediones; Thioctic Acid | 2006 |
Thiazolidinedione derivatives in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
Topics: Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Models, Economic; Obesity; Quality-Adjusted Life Years; Rosiglitazone; Thiazolidinediones; United Kingdom | 2006 |
Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.
Topics: Administration, Oral; Adult; Aged; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Germany; Glycated Hemoglobin; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Models, Economic; Obesity; Quality-Adjusted Life Years; Rosiglitazone; Thiazolidinediones | 2006 |
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Topics: Adult; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Quality-Adjusted Life Years; Rosiglitazone; Spain; Thiazolidinediones | 2006 |
Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Muscle, Skeletal; Rosiglitazone; Thiazolidinediones | 2007 |
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
Topics: Acarbose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypertension; Hypoglycemic Agents; Metformin; Prediabetic State; Rosiglitazone; Safety; Thiazolidinediones | 2007 |
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Troglitazone | 2007 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Prognosis; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
Rosiglitazone : a review of its use in type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Vasodilator Agents; Weight Loss | 2007 |
Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.
Topics: Adult; Clomiphene; Diabetes, Gestational; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infant, Newborn; Lactation; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Complications; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2008 |
Type 2 diabetes: a well-characterised but suboptimally controlled disease. Can we bridge the divide?
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Reference Values; Rosiglitazone; Thiazolidinediones | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
Selecting among ADA/EASD tier 1 and tier 2 treatment options.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glyburide; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Practice Guidelines as Topic; Prognosis; Risk Assessment; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Treatment Outcome | 2009 |
Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?
Topics: Antipsychotic Agents; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Schizophrenia; Thiazolidinediones; Weight Gain | 2009 |
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2010 |
Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.
Topics: Dehydroepiandrosterone Sulfate; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin; Nausea; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Testosterone; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides | 2011 |
Recent diabetes issues affecting the primary care clinician.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency | 2011 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Review Literature as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2011 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United Kingdom | 2012 |
The pharmacogenetics of type 2 diabetes: a systematic review.
Topics: Acarbose; Biomarkers, Pharmacological; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pharmacogenetics; Pioglitazone; Piperidines; Polymorphism, Genetic; Prediabetic State; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2014 |
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment.
Topics: Adipose Tissue; Animals; Cachexia; Diabetes Mellitus, Type 2; Energy Metabolism; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Muscular Atrophy; Neoplasms; Nutritional Support; Proteins; Rosiglitazone; Thiazolidinediones | 2014 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Liver Neoplasms; Metformin; Non-alcoholic Fatty Liver Disease; Pancreatic Neoplasms; Pioglitazone; Precancerous Conditions; Receptors, Somatomedin; Risk Factors; Rosiglitazone; Thiazolidinediones | 2014 |
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Observational Studies as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Update on Youth-Onset Type 2 Diabetes: Lessons Learned from the Treatment Options for Type 2 Diabetes in Adolescents and Youth Clinical Trial.
Topics: Adolescent; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Rosiglitazone; Thiazolidinediones | 2016 |
Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.
Topics: Carbamates; Cause of Death; Cognition Disorders; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Memory Disorders; Metformin; Piperidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2017 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol; Insulin Resistance; Live Birth; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2017 |
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin | 2019 |
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Insulin; Insulin Resistance; Metformin; Mice; Mice, Transgenic; Phosphorylation; Pioglitazone; Rosiglitazone; tau Proteins | 2019 |
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; Microcirculation; Preventive Medicine; Ramipril; Risk Factors; Rosiglitazone; Treatment Outcome | 2019 |
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone | 2019 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
Effects of antidiabetic drugs on psoriasis: A meta-analysis.
Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Pioglitazone; Psoriasis; Rosiglitazone; Treatment Outcome | 2021 |
Youth-onset type 2 diabetes: translating epidemiology into clinical trials.
Topics: Adolescent; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Life Style; Male; Metformin; Prospective Studies; Rosiglitazone; Translational Science, Biomedical; Young Adult | 2021 |
Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Body Weight; Female; Humans; Hypoglycemic Agents; Metformin; Orlistat; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone | 2022 |
Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials.
Topics: Androgens; Dexamethasone; Female; Flutamide; Humans; Hyperandrogenism; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Testosterone | 2023 |
Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mass Screening; Metformin; Obesity; Prediabetic State; Preventive Health Services; Randomized Controlled Trials as Topic; Rosiglitazone | 2022 |
141 trial(s) available for rosiglitazone and metformin
| Article | Year |
|---|---|
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone does not alter the pharmacokinetics of metformin.
Topics: Acidosis, Lactic; Adult; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Blood Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Mice; Mice, Inbred C57BL; Pilot Projects; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Liver Failure; Liver Function Tests; Male; Metformin; Middle Aged; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glyburide; Humans; Hypoglycemic Agents; Metformin; Research Design; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Failure; Treatment Outcome | 2002 |
Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exercise; Fasting; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Leg; Male; Metformin; Middle Aged; Muscle, Skeletal; Oxygen Consumption; Radionuclide Imaging; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Topics: Adipose Tissue; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lactates; Lipids; Male; Metformin; Middle Aged; Placebos; Radiopharmaceuticals; Rosiglitazone; Thiazoles; Thiazolidinediones; Tomography, Emission-Computed; Weight Loss | 2003 |
Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus--a postmarketing study.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2003 |
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glycated Hemoglobin; Glycolysis; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2003 |
Crossover and double blind study with metformin and rosiglitazone in impaired glucose tolerance subjects.
Topics: Adult; Area Under Curve; Blood Glucose; Cholesterol, HDL; Cross-Over Studies; Double-Blind Method; Female; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Rosiglitazone; Thiazolidinediones; Triglycerides | 2003 |
Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2004 |
Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2.
Topics: Adult; Aged; Area Under Curve; Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lactation; Liver; Male; Metformin; Middle Aged; Pregnancy; Rosiglitazone; Tablets; Thiazolidinediones | 2004 |
Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.
Topics: Acetylcholine; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Forearm; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitroprusside; Rosiglitazone; Thiazolidinediones | 2004 |
Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population.
Topics: Algorithms; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Los Angeles; Male; Metformin; Middle Aged; Minority Groups; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2004 |
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
Topics: Adipose Tissue; Cholesterol; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Triglycerides | 2004 |
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Ovulation; Polycystic Ovary Syndrome; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazolidinediones; Venezuela | 2004 |
Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardium; Positron-Emission Tomography; PPAR gamma; Rosiglitazone; Statistics, Nonparametric; Stimulation, Chemical; Thiazolidinediones | 2004 |
Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Topics: Adult; Anovulation; Blood Glucose; Body Weight; Female; Folic Acid; Homocysteine; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Luteinizing Hormone; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazolidinediones; Vitamin B 12 | 2005 |
Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2004 |
Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels.
Topics: Acetylcholine; Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Forearm; Hematocrit; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitroprusside; Rosiglitazone; Thiazolidinediones; Vascular Resistance; Vasodilation; Vasodilator Agents | 2005 |
The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Homeostasis; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Resistin; Rosiglitazone; Thiazolidinediones | 2005 |
Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Thiazolidinediones | 2005 |
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tissue Plasminogen Activator | 2005 |
The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
Topics: Adult; Apolipoproteins B; Biomarkers; Blood Glucose; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipids; Male; Metformin; Middle Aged; Obesity; Postprandial Period; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Rosiglitazone; Safety; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Antioxidants; Blood Glucose; Body Mass Index; Body Weight; Female; Homeostasis; Homocysteine; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Malondialdehyde; Metformin; Models, Statistical; Oxidative Stress; Polycystic Ovary Syndrome; Risk Factors; Rosiglitazone; Smoking; Thiazolidinediones; Time Factors | 2005 |
Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
Topics: Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Triglycerides | 2005 |
Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Blood Glucose; Brachial Artery; Endothelium, Vascular; Fatty Acids, Nonesterified; Glucose Tolerance Test; HIV Infections; Humans; Hypoglycemic Agents; Insulin; Lipodystrophy; Male; Metformin; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones; Vasodilation | 2005 |
Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.
Topics: Adipose Tissue; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Perfusion; Positron-Emission Tomography; Radiopharmaceuticals; Regional Blood Flow; Rosiglitazone; Subcutaneous Tissue; Thiazolidinediones | 2005 |
Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Protease Inhibitors; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2005 |
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2005 |
Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
Topics: Adolescent; Adult; Aged; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Topics: Adult; Androstenedione; Female; Glucose Tolerance Test; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Menstrual Cycle; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazolidinediones; Treatment Outcome | 2005 |
Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Metformin; Polycystic Ovary Syndrome; Prospective Studies; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazolidinediones; Waist-Hip Ratio | 2006 |
Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Tract; Humans; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2005 |
Improving metabolic control leads to better working memory in adults with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Memory; Metformin; Middle Aged; Psychological Tests; Rosiglitazone; Stress, Psychological; Thiazolidinediones | 2006 |
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Rosiglitazone; Tablets; Thiazolidinediones; Treatment Outcome | 2006 |
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2006 |
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Prevention of type 2 diabetes in the prediabetic population.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Male; Metformin; Prediabetic State; Risk Factors; Rosiglitazone; Thiazolidinediones | 2005 |
A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Fertility Agents, Female; Hormones; Humans; Metformin; Ovarian Follicle; Ovulation; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Ultrasonography | 2006 |
Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Aryldialkylphosphatase; Chemokine CCL2; Cholesterol, HDL; HIV; HIV Infections; Humans; Hypoglycemic Agents; Lipodystrophy; Male; Metformin; Middle Aged; Postprandial Period; Rosiglitazone; Thiazolidinediones | 2006 |
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homocysteine; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2006 |
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.
Topics: Administration, Oral; Adult; Blood Proteins; Drug Interactions; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oligoribonucleotides; Protein Binding; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2006 |
Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; Research Design; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Matrix Metalloproteinase 9; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2006 |
Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2006 |
Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study.
Topics: Acanthosis Nigricans; Administration, Oral; Adult; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Obesity; Pilot Projects; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Topics: Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.
Topics: Adult; Age Distribution; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; North America; Racial Groups; Rosiglitazone; Sex Distribution; Thiazolidinediones | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Waist-Hip Ratio; Weight Gain | 2006 |
Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Female; Gene Expression; Gene Expression Profiling; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2007 |
Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
Topics: Adult; Body Composition; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Hyperinsulinism; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Treatment Outcome; Waist-Hip Ratio | 2007 |
Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.
Topics: Blood Glucose; Cholesterol; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins; Male; Metformin; Pioglitazone; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Topics: Adiponectin; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Administration Schedule; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-18; Interleukin-6; Metformin; Multivariate Analysis; Resistin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Multivariate Analysis; Rosiglitazone; Thiazolidinediones; Tunica Intima; Tunica Media; Vasodilator Agents | 2007 |
[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
Topics: Administration, Oral; Belgium; Canada; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Double-Blind Method; European Union; Glyburide; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Quality of Life; Rosiglitazone; Thiazolidinediones; Treatment Outcome; United States | 2007 |
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Topics: Adipose Tissue; Adolescent; Adult; Aged; B-Lymphocytes; Blood Glucose; Body Composition; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Obesity; Obesity, Morbid; Rosiglitazone; Thiazolidinediones; Weight Loss | 2008 |
The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
Topics: Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Endometrium; Female; Follow-Up Studies; Humans; Immunohistochemistry; Linear Models; Metformin; Ovary; Polycystic Ovary Syndrome; Probability; Prospective Studies; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Treatment Outcome | 2007 |
Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Rosiglitazone RECORD study: glucose control outcomes at 18 months.
Topics: Adult; Aged; Australia; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; New Zealand; Prospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2007 |
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Myocardial Infarction; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
Topics: Acarbose; Age of Onset; Aged; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Patient Selection; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Elasticity; Endothelium, Vascular; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Metformin; Middle Aged; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilation | 2007 |
[Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy].
Topics: Adult; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Rosiglitazone; Thiazolidinediones; Uric Acid | 2007 |
Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Administration Schedule; Fasting; Follow-Up Studies; Glucose Tolerance Test; HIV Infections; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Prospective Studies; Protease Inhibitors; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2007 |
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Metformin; Obesity; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
[Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk].
Topics: Adipose Tissue; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pioglitazone; Piperidines; Research Design; Rosiglitazone; Thiazolidinediones | 2008 |
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides | 2008 |
Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Single-Blind Method; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides | 2008 |
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Topics: Age of Onset; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Fractures, Bone; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Analysis of Variance; Androgens; Female; Gene Expression; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Italy; Leptin; Male; Metformin; Middle Aged; Obesity; Overweight; Resistin; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2008 |
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2008 |
Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Diet Therapy; Exercise Therapy; Fatty Liver; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test.
Topics: Adult; Area Under Curve; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Metformin; Prospective Studies; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2008 |
Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome.
Topics: Androgens; Brachial Artery; C-Reactive Protein; Cardiovascular Diseases; Endothelium, Vascular; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Menstrual Cycle; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Vasodilation | 2008 |
[Effect of insulin plus rosiglitazone or metformin on serum N-terminal pro-brain natriuretic peptide in type 2 diabetes mellitus: a randomized-controlled study].
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Rosiglitazone; Thiazolidinediones | 2008 |
A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fibrinolysis; Follow-Up Studies; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2008 |
Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease.
Topics: Adiponectin; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combination; Echocardiography, Doppler, Pulsed; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Malondialdehyde; Metformin; Middle Aged; Myocardial Contraction; Myocardium; Oxidative Stress; Pilot Projects; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2008 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United States; Veterans | 2009 |
Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Patient Satisfaction; Piperidines; Rosiglitazone; Tablets; Thiazolidinediones; Young Adult | 2009 |
Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Pressure; Carboxypeptidase B2; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Simvastatin; Thiazolidinediones | 2009 |
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Topics: Administration, Oral; Angina, Unstable; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Drug Utilization; Female; Fractures, Bone; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Neoplasms; Prospective Studies; Rosiglitazone; Sex Factors; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Pressure; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; Fibroblast Growth Factors; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2009 |
Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans.
Topics: Adiponectin; Adult; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Intracellular Space; Male; Metformin; Middle Aged; Molecular Weight; Protein Isoforms; Protein Multimerization; Rosiglitazone; Substrate Specificity; Thiazolidinediones; Young Adult | 2009 |
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Transaminases; Treatment Outcome | 2010 |
Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
Topics: Chemokine CCL2; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Vascular Resistance | 2009 |
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
Topics: Aged; Berberine; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liver Diseases; Male; Metformin; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Insulin; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2010 |
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
Topics: Adult; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Time; Treatment Outcome; Weight Gain | 2010 |
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Topics: Adipokines; Aged; Apelin; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Ghrelin; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nicotinamide Phosphoribosyltransferase; Rosiglitazone; Thiazolidinediones; Waist-Hip Ratio | 2010 |
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Bone Resorption; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Osteogenesis; Rosiglitazone; Thiazolidinediones | 2010 |
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Venoms; Weight Gain | 2010 |
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Thiazolidines; Treatment Outcome | 2010 |
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones | 2011 |
Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy.
Topics: Area Under Curve; Biomarkers; Cholesterol; Fatty Acids, Nonesterified; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxybutyrates; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Netherlands; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides | 2011 |
Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Lipids; Male; Metformin; Middle Aged; Neoadjuvant Therapy; Rosiglitazone; Serpins; Thiazolidinediones | 2011 |
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2011 |
The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus.
Topics: Adult; C-Peptide; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Humans; Interleukin-6; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazolidinediones; Triglycerides; Young Adult | 2011 |
Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study.
Topics: Administration, Oral; Adult; Anthropometry; Asian People; Body Composition; China; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Young Adult | 2011 |
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Losartan; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2011 |
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Rosiglitazone; Survival Analysis; Thiazolidinediones; Treatment Failure; Weight Loss | 2012 |
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2012 |
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Receptors, Glucagon; Rosiglitazone; Thiazolidinediones; Venoms | 2012 |
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Rosiglitazone; Thiazolidinediones; Time Factors | 2013 |
Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome.
Topics: Adult; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Metformin; Ovary; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Ultrasonography | 2013 |
Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Remodeling; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Drug Substitution; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Postmenopause; Rosiglitazone; Thiazolidinediones | 2013 |
The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT).
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Interleukin-6; Lipoproteins; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2013 |
Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus.
Topics: Aged; Aryldialkylphosphatase; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Homocysteine; Humans; Hypoglycemic Agents; Insulin; Male; Malondialdehyde; Metabolome; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2013 |
Vitamin D supplementation in patients with diabetes mellitus type 2 on different therapeutic regimens: a one-year prospective study.
Topics: Administration, Oral; Adult; Biomarkers; Blood Glucose; Case-Control Studies; Cholecalciferol; Diabetes Mellitus, Type 2; Dietary Supplements; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Rosiglitazone; Saudi Arabia; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Vitamin D; Young Adult | 2013 |
Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Antioxidants; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Insulin-Secreting Cells; Lipids; Male; Malondialdehyde; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Thioctic Acid; Time Factors | 2013 |
Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Calcium-Binding Proteins; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Prospective Studies; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2014 |
Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study.
Topics: Adolescent; Blood Glucose; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Remodeling; Cell Lineage; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Osteoclasts; Postmenopause; Rosiglitazone; Stem Cells; Thiazolidinediones | 2014 |
Cancer and bone fractures in observational follow-up of the RECORD study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoplasms; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Thromboplastin | 2015 |
Metformin treatment significantly enhances intestinal glucose uptake in patients with type 2 diabetes: Results from a randomized clinical trial.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Intestinal Mucosa; Male; Metformin; Middle Aged; Rats; Rosiglitazone; Thiazolidinediones | 2017 |
Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study.
Topics: Adolescent; Biomarkers; Cardiovascular Diseases; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet Therapy; Drug Therapy, Combination; Echocardiography; Exercise Therapy; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypoglycemic Agents; Male; Metformin; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Ventricular Function, Left | 2018 |
Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes.
Topics: Biomarkers; Bone and Bones; Bone Remodeling; Collagen Type I; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Male; Metformin; Middle Aged; Peptide Fragments; Peptides; Procollagen; Rosiglitazone | 2018 |
Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study.
Topics: Adolescent; Androgens; Aspartate Aminotransferases; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Estradiol; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Menstruation Disturbances; Metformin; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone | 2018 |
Pharmacoeconomic evaluation of glimepiride combined with other drugs in the treatment of diabetes.
Topics: Acarbose; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds | 2018 |
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS.
Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; India; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Spironolactone; Treatment Outcome; Young Adult | 2020 |
Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Prospective Studies; Rosiglitazone; Treatment Outcome; Waist Circumference; Young Adult | 2020 |
Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure.
Topics: Adolescent; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucokinase; Hepatocyte Nuclear Factor 4; Humans; Insulin Resistance; Insulin-Secreting Cells; Life Style; Longitudinal Studies; Male; Metformin; Mutation; Pediatric Obesity; Risk Reduction Behavior; Rosiglitazone | 2020 |
Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study.
Topics: Adolescent; Age of Onset; Cell Adhesion Molecules; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Male; Metformin; Risk Reduction Behavior; Rosiglitazone | 2020 |
Consumption of Beverages Containing Low-Calorie Sweeteners, Diet, and Cardiometabolic Health in Youth With Type 2 Diabetes.
Topics: Adolescent; Beverages; Body Mass Index; Cardiometabolic Risk Factors; Child; Diabetes Mellitus, Type 2; Diet; Diet Records; Dietary Sugars; Drug Combinations; Energy Intake; Female; Humans; Life Style; Longitudinal Studies; Male; Metformin; Rosiglitazone; Surveys and Questionnaires; Sweetening Agents; Thiazoles | 2020 |
Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Rosiglitazone | 2021 |
194 other study(ies) available for rosiglitazone and metformin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Novel substituted aminoalkylguanidines as potential antihyperglycemic and food intake-reducing agents.
Topics: Animals; Anti-Obesity Agents; Drinking; Eating; Guanidines; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Dyslipidemias; Glycogen Phosphorylase; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Quinolines | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Synthesis of propiophenone derivatives as new class of antidiabetic agents reducing body weight in db/db mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Eating; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Mice; Mice, Inbred C57BL; Propiophenones; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Rats, Sprague-Dawley; Rats, Wistar; Streptozocin; Weight Loss | 2012 |
Flavone-based novel antidiabetic and antidyslipidemic agents.
Topics: Animals; Biological Availability; Cholesterol; Cricetinae; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Flavones; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Streptozocin; Structure-Activity Relationship; Triglycerides | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Alanine Transaminase; Animals; Barbiturates; Body Weight; Cholesterol; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Female; Glucose; Glucose Tolerance Test; Hep G2 Cells; Humans; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tissue Distribution; Triglycerides | 2012 |
Thiazolidin-4-one and thiazinan-4-one derivatives analogous to rosiglitazone as potential antihyperglycemic and antidyslipidemic agents.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Cell Differentiation; Cell Line; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Glucose; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Chemical; Molecular Structure; Muscle, Skeletal; Rosiglitazone; Structure-Activity Relationship; Thiazines; Thiazolidinediones; Thiazolidines; Triglycerides | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Hep G2 Cells; Humans; Indoleacetic Acids; Mice; Mice, Mutant Strains; Molecular Structure | 2015 |
Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents.
Topics: Alkaloids; Animals; Blood Glucose; Carbazoles; Diabetes Mellitus, Experimental; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Molecular Structure; Murraya; Muscle Fibers, Skeletal; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Streptozocin | 2016 |
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
Topics: Hypoglycemic Agents; Ligands; Mitochondrial Proteins; Protein Binding; Small Molecule Libraries; Thiazolidinediones | 2016 |
Novel berberine-based derivatives with potent hypoglycemic activity.
Topics: Berberine; Humans; Hypoglycemic Agents | 2019 |
Structure-activity relationship and hypoglycemic activity of tricyclic matrines with advantage of treating diabetic nephropathy.
Topics: Alkaloids; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Female; Hep G2 Cells; Humans; Hypoglycemic Agents; Kidney; Male; Matrines; Mice, Inbred C57BL; Molecular Structure; Pancreas; Quinolizines; Structure-Activity Relationship | 2020 |
Oral antidiabetic agents safe with renal disease?
Topics: Aged; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Kidney Diseases; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adipose Tissue; Adrenal Glands; Adrenalectomy; Analysis of Variance; Animals; Blood Glucose; Corticosterone; Eating; Hydroxysteroid Dehydrogenases; Hypertrophy; Hypoglycemic Agents; Insulin; Liver; Male; Metformin; Obesity; Omentum; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2000 |
[Type 2 diabetes. How can the infarction risk be reduced?].
Topics: Acarbose; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vasodilator Agents | 2002 |
The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.
Topics: AMP-Activated Protein Kinases; Animals; Catalysis; Enzyme Activation; Hypoglycemic Agents; Metformin; Mice; Mice, Transgenic; Multienzyme Complexes; Phosphorylation; Protein Serine-Threonine Kinases; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2002 |
Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?
Topics: Animals; Appetite; Body Weight; Corticosterone; Dexamethasone; Female; Gene Expression; Glucocorticoids; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Organ Size; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Receptors, Glucocorticoid; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
[When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent].
Topics: Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Topics: Adipose Tissue; Biological Transport; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Lipids; Liver; Male; Metformin; Middle Aged; Placebos; Radiopharmaceuticals; Regression Analysis; Rosiglitazone; Thiazolidinediones; Tomography, Emission-Computed | 2003 |
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Topics: Carbamates; Cohort Studies; Decision Trees; Diabetes Mellitus, Type 2; Direct Service Costs; Drug Costs; Drug Therapy, Combination; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Managed Care Programs; Markov Chains; Metformin; Models, Economic; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2003 |
Effects of insulin-sensitising agents in mice with hepatic insulin resistance.
Topics: Animals; Blood Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Metformin; Mice; Mice, Knockout; Mice, Obese; Receptor, Insulin; Rosiglitazone; Thiazolidinediones | 2004 |
[Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].
Topics: Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Compliance; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Simultaneous determination of metformin in combination with rosiglitazone by reversed-phase liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Metformin; Reference Standards; Reproducibility of Results; Rosiglitazone; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Thiazolidinediones | 2004 |
Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?
Topics: Animals; Electron Transport Complex I; Energy Metabolism; Hypoglycemic Agents; Male; Metformin; Mitochondria; Muscle, Skeletal; Oxygen Consumption; Pioglitazone; Potassium Chloride; Rats; Rats, Sprague-Dawley; Rosiglitazone; Rotenone; Thiazolidinediones | 2004 |
Increased adipose tissue expression of Grb14 in several models of insulin resistance.
Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; Adipose Tissue; Animals; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Gene Expression Regulation; Insulin; Insulin Resistance; Liver; Metformin; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscles; Obesity; Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2004 |
[Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats].
Topics: Animals; Blood Glucose; Dietary Fats; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain | 2004 |
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients: response to Poulsen et al.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglycemic Agents; Insulin; Insulin Aspart; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
Twice-Daily NPH or mixture insulins versus triple therapy: apples versus oranges: response to Poulsen et al.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Insulin; Insulin Aspart; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin.
Topics: Animals; Blood Proteins; Fatty Acids; Fatty Acids, Nonesterified; Glycerol; Heparin; Hypoglycemic Agents; Insulin Resistance; Lipids; Metformin; Rats; Rosiglitazone; Thiazolidinediones; Triglycerides | 2004 |
Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes.
Topics: Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Regression Analysis; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulphonylurea agent: response to Roy et al.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
[Rosiglitazone-metformin fixed dose combination for treatment of type 2 diabetes].
Topics: Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Female; Humans; Hypoglycemic Agents; Liver Failure; Male; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Topics: Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Compliance; Rosiglitazone; Thiazolidinediones | 2004 |
Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1.
Topics: Adult; Aminoimidazole Carboxamide; Biopsy; Cells, Cultured; Female; Glucose; Glucose Transporter Type 4; Glycogen; Humans; Insulin; Male; Metformin; Middle Aged; Monosaccharide Transport Proteins; Muscle Fibers, Skeletal; Muscle Proteins; Muscle, Skeletal; Reference Values; Ribonucleotides; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2005 |
Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide.
Topics: Amyloid; Animals; Gene Expression Regulation; Humans; Islet Amyloid Polypeptide; Islets of Langerhans; Metformin; Mice; Mice, Transgenic; Rosiglitazone; Thiazolidinediones | 2005 |
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Topics: Administration, Oral; Animals; Benzimidazoles; Blood Glucose; Dose-Response Relationship, Drug; Glucose; Glucose Intolerance; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Metformin; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
Management of diabetes during Ramadan.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Gliclazide; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Rosiglitazone; Thiazolidinediones | 2005 |
Stockpiling of ovarian follicles and the response to rosiglitazone.
Topics: Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Middle Aged; Ovarian Follicle; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Rosiglitazone; Thiazolidinediones | 2005 |
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.
Topics: Aged; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Electromyography; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Muscular Diseases; Rosiglitazone; Thiazolidinediones | 2005 |
Summaries for patients. HIV lipodystrophy: rosiglitazone or metformin?
Topics: Adipose Tissue; Adolescent; Adult; Aged; Blood Glucose; Brachial Artery; Endothelium, Vascular; Fatty Acids, Nonesterified; Glucose Tolerance Test; HIV Infections; Humans; Hypoglycemic Agents; Insulin; Lipodystrophy; Male; Metformin; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones; Vasodilation | 2005 |
Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes.
Topics: Aged; Blood Pressure; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones | 2005 |
Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Cholesterol; Cyclohexanes; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Metformin; Nateglinide; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization.
Topics: Animals; Cholestenone 5 alpha-Reductase; Glucocorticoids; Hypoglycemic Agents; Insulin; Liver; Metformin; Obesity; Oxidoreductases; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2005 |
Effects of metformin and oleic acid on adipocyte expression of resistin.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Antimetabolites; Cell Differentiation; Cell Line; Deoxyglucose; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Metformin; Mice; Muscle Cells; Muscle, Skeletal; Oleic Acid; Protein Kinase Inhibitors; Resistin; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2006 |
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Luteinizing Hormone; Menstrual Cycle; Menstruation; Metformin; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Thinness | 2005 |
Effects of rosiglitazone and metformin on pancreatic beta cell gene expression.
Topics: Active Transport, Cell Nucleus; Anilides; Animals; Cell Line; Cell Nucleus; DNA; Gene Expression; Glucose; Hepatocyte Nuclear Factor 3-beta; Homeodomain Proteins; Insulin-Secreting Cells; Metformin; Mice; Proinsulin; Promoter Regions, Genetic; Protein Binding; Rats; Rosiglitazone; Thiazolidinediones; Time Factors; Trans-Activators | 2006 |
Optimal treatments for the metabolic syndrome.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Rosiglitazone; Thiazolidinediones | 2006 |
[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cholesterol; Dietary Fats; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; fas Receptor; Fatty Liver; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha | 2006 |
Total cellular calcium and magnesium content of cultured human peripheral blood mononuclear cells following exposure to antidiabetic drugs.
Topics: Adult; Calcium; Cells, Cultured; Diazoxide; Glyburide; Humans; Hypoglycemic Agents; Leukocytes; Magnesium; Metformin; Middle Aged; Potassium Channels; Rosiglitazone; Thiazolidinediones | 2006 |
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Topics: Animals; Anticholesteremic Agents; Azetidines; Choline Deficiency; Drug Therapy, Combination; Ezetimibe; Fats; Fatty Liver; Hypoglycemic Agents; Lipid Peroxidation; Liver; Male; Metformin; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rosiglitazone; Tetrazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Ovarian stockpiling in polycystic ovary syndrome, infertility, and the combined use of rosiglitazone and metformin.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Infertility, Female; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Rosiglitazone; Thiazolidinediones | 2006 |
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Thiazolidinediones for initial treatment of type 2 diabetes?
Topics: Algorithms; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones; Weight Gain | 2006 |
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Topics: Blood Glucose; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Markov Chains; Metformin; Middle Aged; Models, Economic; Monte Carlo Method; Pioglitazone; Rosiglitazone; Thiazolidinediones; United Kingdom | 2007 |
Letter to the editor in reference to article titled: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2007 |
Glycemic durability of monotherapy for diabetes.
Topics: Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Rosiglitazone; Thiazolidinediones | 2007 |
The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease.
Topics: Adult; Biopsy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Exercise Therapy; Fatty Liver; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Transaminases; Treatment Outcome; Vasodilator Agents | 2007 |
Larval zebrafish as a model for glucose metabolism: expression of phosphoenolpyruvate carboxykinase as a marker for exposure to anti-diabetic compounds.
Topics: Animals; Blood Glucose; Cyclic AMP; Dexamethasone; Glipizide; Hypoglycemic Agents; Larva; Metformin; Models, Animal; Phosphoenolpyruvate Carboxykinase (GTP); Rosiglitazone; Thiazolidinediones; Tretinoin; Zebrafish | 2007 |
Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Humans; Hypoglycemic Agents; Metformin; Reproducibility of Results; Rosiglitazone; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thiazolidinediones | 2007 |
Thiazolidinedione induced thyroid associated orbitopathy.
Topics: Diplopia; Disease Progression; Drug Therapy, Combination; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Metformin; Middle Aged; Propranolol; Propylthiouracil; Retreatment; Rosiglitazone; Thiazolidinediones | 2007 |
[Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
Topics: Androgen Antagonists; Blood Glucose; Body Composition; Cyproterone Acetate; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ethinyl Estradiol; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2006 |
Hospital admission associated with Medicare Part D "doughnut hole".
Topics: Aged; Diabetes Mellitus; Drug Prescriptions; Female; Humans; Hypoglycemic Agents; Insurance, Pharmaceutical Services; Medicare; Metformin; Patient Readmission; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiotoxicity--weighing the evidence.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
Coronary heart disease outcomes in patients receiving antidiabetic agents.
Topics: Adolescent; Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; United States | 2007 |
Response to Pokharna and Kanna: initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2008 |
[ADOPT study. Glitazone controls diabetes progression].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Long-Term Care; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
Pioglitazone: an anti-diabetic compound with anti-aging properties.
Topics: Animals; Basal Metabolism; Dose-Response Relationship, Drug; Drosophila melanogaster; Fertility; Glipizide; Hypoglycemic Agents; Insulin; Longevity; Metformin; Models, Biological; Pioglitazone; Population Density; Research Design; Rosiglitazone; Sexual Behavior, Animal; Signal Transduction; Thiazolidinediones; Time Factors | 2007 |
[New rank order of antidiabetic drugs. Using glitazone before sulfonylurea drugs? (interview by Dr. Dirk Einecke)].
Topics: Diabetes Mellitus, Type 2; Disease Progression; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
[ADOPT study: Reevaluation of antidiabetic drugs. Control of diabetes].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
[Consulting Prof. Dr. Stephan Matthaei. Quakenbrück diabetes center. Prescription relevant conclusions].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Long-Term Care; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Preventing diabetes, Part II: an action plan.
Topics: Diabetes Mellitus; Diet; Exercise; Humans; Hypoglycemic Agents; Life Style; Metformin; Obesity; Rosiglitazone; Smoking; Thiazolidinediones; Weight Loss | 2007 |
Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?
Topics: Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodoxone; Dehydroepiandrosterone; Endocrine Disruptors; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Male; Metformin; Middle Aged; Radioimmunoassay; Rosiglitazone; Testosterone; Thiazolidinediones; Valproic Acid | 2007 |
Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats.
Topics: Animals; Apoptosis; Blood Glucose; Glyburide; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Models, Biological; Random Allocation; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2008 |
Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.
Topics: Abnormalities, Multiple; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Rosiglitazone; Syndrome; Thiazolidinediones | 2007 |
[Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
Topics: Adolescent; Adult; Capillary Permeability; Case-Control Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Microcirculation; Microscopic Angioscopy; Obesity; Plethysmography; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2007 |
AMP-activated protein kinase subunit interactions: beta1:gamma1 association requires beta1 Thr-263 and Tyr-267.
Topics: AMP-Activated Protein Kinases; Animals; Catalytic Domain; Chlorocebus aethiops; COS Cells; Exercise; Glucose; Hormones; Humans; Hypoglycemic Agents; Liver; Metformin; Multienzyme Complexes; Mutagenesis, Site-Directed; Protein Binding; Protein Serine-Threonine Kinases; Protein Structure, Quaternary; Rats; Rosiglitazone; Stress, Physiological; Thiazolidinediones | 2008 |
Choosing first-line therapy for management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2008 |
Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.
Topics: Administration, Oral; Animals; Biological Transport; Carbamates; Cell Line; Dogs; Hepatocytes; Humans; Hypoglycemic Agents; Kidney; Kinetics; Liver; Liver-Specific Organic Anion Transporter 1; Metformin; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Piperidines; Pravastatin; Recombinant Proteins; Rosiglitazone; Solute Carrier Organic Anion Transporter Family Member 1B3; Thiazolidinediones | 2008 |
[The effectiveness in type 2 diabetes prevention: a forced landing to reality].
Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Life Style; Metformin; Patient Education as Topic; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Topics: Cohort Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Outcome Assessment, Health Care; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
Topics: Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Incidence; Male; Markov Chains; Metformin; Middle Aged; Registries; Rosiglitazone; Sulfonylurea Compounds; Thailand; Thiazolidinediones; Treatment Outcome | 2008 |
Re: "Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome", Sinha SK et al., JPEM 2007; 20: 1045-1052.
Topics: Child; Deafness; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Male; Metformin; Nystagmus, Congenital; Obesity; Retinitis Pigmentosa; Rosiglitazone; Syndrome; Thiazolidinediones | 2008 |
Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.
Topics: Amputation, Surgical; Blindness; Cardiovascular Diseases; Computer Simulation; Diabetes Complications; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Biological; Prognosis; Renal Insufficiency; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United Kingdom | 2008 |
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Models, Economic; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
Treatment options in insulin resistance obesity-related acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Adult; Calcitriol; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Octreotide; Retinoids; Rosiglitazone; Thiazolidinediones; Vitamin D | 2008 |
Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment.
Topics: Adult; Aged; Apoptosis; C-Reactive Protein; Case-Control Studies; CD11b Antigen; Diabetes Mellitus, Type 2; Fibrinogen; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Leukocytes, Mononuclear; Metformin; Middle Aged; Oxidative Stress; Rosiglitazone; Superoxides; Thiazolidinediones; Transferrin | 2008 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
[Avandia and avandamet in the treatment of patients with diabetes mellitus type 2: effects on secretion of some fat tissue hormones].
Topics: Adiponectin; Adipose Tissue; Diabetes Mellitus, Type 2; Drug Combinations; Female; Fibrinolytic Agents; Ghrelin; Humans; Hypoglycemic Agents; Insulin; Leptin; Male; Metformin; Middle Aged; Resistin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2008 |
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Bypass; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Smoking; Sulfonylurea Compounds; Survival Analysis; Survivors; Thiazolidinediones | 2009 |
Diabetes treatment.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Metformin; Peroxisome Proliferator-Activated Receptors; Receptors, G-Protein-Coupled; Rosiglitazone; Thiazolidinediones | 2009 |
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
Topics: Aged; Comorbidity; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insurance, Health, Reimbursement; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States | 2009 |
Thiazolidinediones and clinical outcomes in type 2 diabetes.
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
Topics: Aged; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Demography; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prevalence; Regression Analysis; Rosiglitazone; Spinal Fractures; Thiazolidinediones | 2009 |
Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Medical Records Systems, Computerized; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Regression Analysis; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats.
Topics: Animals; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dinoprostone; Gastric Mucosa; Hypoglycemic Agents; Indomethacin; Male; Malondialdehyde; Metformin; Mucins; Nitric Oxide; Rats; Rats, Wistar; Rosiglitazone; Stomach Ulcer; Thiazolidinediones | 2010 |
Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones | 2009 |
Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies.
Topics: Animals; Blotting, Western; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Experimental; Enzyme Activation; Fibrinolytic Agents; Hypoglycemic Agents; Male; Metformin; Osteoblasts; Rats; Rats, Sprague-Dawley; Rosiglitazone; Stem Cells; Thiazolidinediones | 2010 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Lactic Acid; Lysine; Metabolomics; Metformin; Piperidines; Rosiglitazone; Thiazolidinediones; Uric Acid; Valine | 2009 |
Spectrophotometric and HPLC determinations of anti-diabetic drugs, rosiglitazone maleate and metformin hydrochloride, in pure form and in pharmaceutical preparations.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Combinations; Hypoglycemic Agents; Metformin; Molecular Structure; Rosiglitazone; Spectrophotometry; Tablets; Thiazoles; Thiazolidinediones | 2009 |
In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy.
Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Energy Metabolism; Fatty Acids; Gene Expression Regulation; Glucose; Glucose Transport Proteins, Facilitative; Heart Diseases; Hemodynamics; Hypoglycemic Agents; Male; Metformin; Myocardium; Oxidation-Reduction; Phenotype; Positron-Emission Tomography; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Time Factors | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin.
Topics: Adenosine Triphosphate; Biological Transport; Carbon Radioisotopes; Carrier Proteins; Cell Polarity; Diabetes, Gestational; Drug Interactions; Female; Glyburide; Humans; Hypoglycemic Agents; Maternal-Fetal Exchange; Metformin; Microvilli; Placenta; Pregnancy; Rosiglitazone; Thiazolidinediones; Tritium | 2010 |
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones | 2011 |
Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Topics: Aged; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2011 |
Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2010 |
Preventing type 2 diabetes with low-dose combinations.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice.
Topics: Animals; Body Weight; Cardiomegaly; Drug Therapy, Combination; Eating; Male; Metformin; Mice; Mice, Inbred BALB C; Obesity; Rosiglitazone; Thiazolidinediones; Weight Gain | 2010 |
A systems biology approach to identify effective cocktail drugs.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Gene Expression Profiling; Hypoglycemic Agents; Metformin; Models, Molecular; Pilot Projects; Rosiglitazone; Systems Biology; Thiazolidinediones | 2010 |
Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Anilides; Anti-Inflammatory Agents; Antimetabolites; Asthma; Cells, Cultured; Chromans; Cytokines; Enzyme Activators; Enzyme Inhibitors; Gene Knockdown Techniques; Humans; Hypoglycemic Agents; Inflammation Mediators; Metformin; Myocytes, Smooth Muscle; PPAR gamma; Pyrazoles; Pyrimidines; Respiratory System; Ribonucleotides; Rosiglitazone; Thiazolidinediones; Troglitazone; Vidarabine | 2011 |
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2010 |
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Remission Induction; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2010 |
Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.
Topics: Adiposity; Analysis of Variance; Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Metformin; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2011 |
Serum sialic acid changes in type 2 diabetic patients on metformin or rosiglitazone treatment.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; N-Acetylneuraminic Acid; Risk; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides | 2010 |
Simultaneous determination and pharmacokinetic study of metformin and rosiglitazone in human plasma by HPLC-ESI-MS.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Least-Squares Analysis; Male; Metformin; Phenformin; Reproducibility of Results; Rosiglitazone; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Thiazolidinediones | 2011 |
Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007.
Topics: Decision Making, Organizational; Diabetes Mellitus, Type 2; Drug Approval; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Theoretical; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2011 |
Determination of rosiglitazone and metformin in human serum by CE-ESI-MS.
Topics: Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazolidinediones | 2011 |
[Clinical vignette. Which combination of oral glucose-lowering agents to use after failure of metformin monotherapy in type 2 diabetes?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Failure | 2011 |
Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Theoretical; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2011 |
Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neoplasms; Metformin; PPAR alpha; PPAR gamma; Rats; Ribonucleosides; Rosiglitazone; Thiazolidinediones; Transcriptional Activation | 2011 |
Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2011 |
What's next for diabetes prevention?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Insulin-Secreting Cells; Male; Metformin; Rosiglitazone; Thiazolidinediones | 2011 |
Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation.
Topics: Animals; Cell Proliferation; Cells, Cultured; Drug Evaluation, Preclinical; Exenatide; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Mice; Mice, Inbred C57BL; Peptides; Receptors, Glucagon; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Tolbutamide; Up-Regulation; Venoms; Wnt4 Protein | 2011 |
Elevated circulating vaspin levels were decreased by rosiglitazone therapy in T2DM patients with poor glycemic control on metformin alone.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Rosiglitazone; Serpins; Thiazolidinediones | 2011 |
Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats.
Topics: Adipocytes; Alkaline Phosphatase; AMP-Activated Protein Kinases; Animals; Bone Marrow Cells; Bone Regeneration; Cell Differentiation; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Drug Interactions; Extracellular Space; Femur; Gene Expression Regulation; Male; Metformin; Osteogenesis; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Stem Cells; Thiazolidinediones | 2011 |
RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.
Topics: Animals; Antisense Elements (Genetics); Atorvastatin; Gemfibrozil; GTPase-Activating Proteins; Heptanoic Acids; Hypoglycemic Agents; Hypolipidemic Agents; Metabolic Syndrome; Metformin; Mice; Mice, Knockout; Pyrroles; Rosiglitazone; Thiazolidinediones | 2011 |
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Non-alcoholic Fatty Liver Disease; Rosiglitazone; Thiazolidinediones | 2011 |
Fixed dose combination diabetes medicines - usage in the Australian veteran population.
Topics: Aged; Aged, 80 and over; Australia; Diabetes Mellitus, Type 2; Drug Combinations; Drug Prescriptions; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Practice Patterns, Physicians'; Rosiglitazone; Thiazolidinediones; Veterans | 2011 |
Rosiglitazone and metformin have opposite effects on intestinal absorption of oligopeptides via the proton-dependent PepT1 transporter.
Topics: Adenylate Kinase; Animals; Base Sequence; Caco-2 Cells; DNA Primers; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Humans; Hypoglycemic Agents; Intestinal Absorption; Male; Metformin; Mice; Mice, Inbred C57BL; Oligopeptides; Peptide Transporter 1; Protons; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Symporters; Thiazolidinediones | 2012 |
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Hospitalization; Humans; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2011 |
Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Drug Combinations; Edema; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Mexico; Middle Aged; Pharmacovigilance; Prospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2012 |
Fenugreek attenuation of diabetic nephropathy in alloxan-diabetic rats: attenuation of diabetic nephropathy in rats.
Topics: Alloxan; Animals; Anti-Inflammatory Agents; Antioxidants; Catalase; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glutathione; Interleukin-6; Kidney; Lipid Peroxidation; Malondialdehyde; Metformin; Oxidative Stress; Phytotherapy; Plant Extracts; Rats; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Trigonella | 2012 |
Comparative effectiveness of incident oral antidiabetic drugs on kidney function.
Topics: Administration, Oral; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2012 |
Metformin prevents the development of chronic heart failure in the SHHF rat model.
Topics: Animals; Blood Glucose; Blood Pressure; Chronic Disease; Gene Expression Regulation; Heart Failure; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Ventricular Remodeling | 2012 |
Hypoglycemic effect and mechanism of a proteoglycan from ganoderma lucidum on streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Fruiting Bodies, Fungal; Hypoglycemic Agents; Insulin; Lipids; Liver; Male; Metformin; Muscle, Skeletal; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proteoglycans; Rats; Rats, Sprague-Dawley; Reishi; Rosiglitazone; Thiazolidinediones | 2012 |
TODAY--a stark glimpse of tomorrow.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Rosiglitazone; Thiazolidinediones | 2012 |
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose Intolerance; Glyburide; Hypoglycemic Agents; Insulin Resistance; Metformin; Olanzapine; Rats; Rosiglitazone; Thiazolidinediones | 2012 |
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.
Topics: Adolescent; Apoptosis; Cell Line, Tumor; Cell Proliferation; Child; Child, Preschool; Daunorubicin; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Rosiglitazone; Thiazolidinediones; TOR Serine-Threonine Kinases | 2012 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |
The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice.
Topics: Animals; Blood Glucose; Bone Density; Bone Morphogenetic Protein 2; Core Binding Factor Alpha 1 Subunit; Fatty Acid-Binding Proteins; Female; Femur; Insulin Resistance; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2012 |
Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models.
Topics: Animals; Biguanides; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Injections, Intraventricular; Injections, Spinal; Metformin; Mice; Mice, Inbred ICR; Pioglitazone; Rosiglitazone; Streptozocin; Thiazolidinediones | 2012 |
Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis.
Topics: Acrylamides; Adult; AMP-Activated Protein Kinase Kinases; Cell Line, Tumor; Cytokines; Enzyme Inhibitors; Estradiol; Female; Follicle Stimulating Hormone; Gene Expression Regulation; Granulosa Cells; Humans; Insulin-Like Growth Factor I; Metformin; Nicotinamide Phosphoribosyltransferase; Piperidines; Primary Cell Culture; Progesterone; Protein Kinases; Recombinant Proteins; Rosiglitazone; Signal Transduction; Sirtuin 1; Thiazolidinediones | 2013 |
Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Middle Aged; Nutrition Surveys; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States | 2013 |
GSK fights compensation claims from UK patients who took rosiglitazone.
Topics: Compensation and Redress; Drug Combinations; Drug Industry; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazoles; Thiazolidinediones; United Kingdom | 2013 |
Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; United States; Veterans | 2013 |
Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Analysis of Variance; Animals; Bariatric Surgery; Diet, High-Fat; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Genes, p53; Humans; Inflammation; Insulin Resistance; Male; Metformin; Mice; Mice, Knockout; Obesity; Omentum; Rosiglitazone; Thiazolidinediones | 2014 |
Resistin, an adipokine, may affect the improvement of insulin sensitivity in the metabolic syndrome patient treated with metformin.
Topics: Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Models, Biological; Resistin; Rosiglitazone; Thiazolidinediones | 2013 |
Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine.
Topics: Animals; Benzodiazepines; Disease Models, Animal; Drug Therapy, Combination; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Glyburide; Hypoglycemic Agents; Insulin; Metformin; Olanzapine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Selective Serotonin Reuptake Inhibitors; Thiazolidinediones; Time Factors | 2014 |
Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models.
Topics: Adipocytes; Aminopyridines; Animals; Diabetes Mellitus, Type 2; Drug Discovery; Glucose; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Mice; Mice, Mutant Strains; Rosiglitazone; Sulfonamides; Thiazolidinediones | 2013 |
Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo.
Topics: Aminoimidazole Carboxamide; Animals; Bezafibrate; HeLa Cells; Humans; Metformin; Mice; Mitochondrial Proteins; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Resveratrol; Ribonucleotides; Rosiglitazone; Signal Transduction; Stilbenes; Thiazolidinediones; Transcription Factors | 2014 |
Repression of integrin-linked kinase by antidiabetes drugs through cross-talk of PPARγ- and AMPKα-dependent signaling: role of AP-2α and Sp1.
Topics: AMP-Activated Protein Kinases; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Mutation; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; PPAR gamma; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Sp1 Transcription Factor; Thiazolidinediones; Transcription Factor AP-2 | 2014 |
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Humulus; Hypoglycemic Agents; Insulin; Insulin Resistance; Macrophages; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Monocytes; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression.
Topics: alpha-2-HS-Glycoprotein; Anilides; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expression; Hepatocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2014 |
PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
Topics: Adipogenesis; Animals; Cell Differentiation; Cells, Cultured; Chromans; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Droplets; Metformin; Mice; Osteoblasts; Osteoclasts; Osteogenesis; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Troglitazone | 2014 |
Use of antidiabetic drugs in the U.S., 2003-2012.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States | 2014 |
CHEMERIN (RARRES2) decreases in vitro granulosa cell steroidogenesis and blocks oocyte meiotic progression in bovine species.
Topics: Animals; Blotting, Western; Cattle; Chemokines; Estradiol; Female; Granulosa Cells; Immunohistochemistry; Insulin; Insulin-Like Growth Factor I; Meiosis; Metformin; Mitogen-Activated Protein Kinases; Oocytes; Ovary; Progesterone; Real-Time Polymerase Chain Reaction; Receptors, Chemokine; RNA; Rosiglitazone; Thiazolidinediones | 2014 |
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fee-for-Service Plans; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Managed Care Programs; Maryland; Medicaid; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States; Young Adult | 2014 |
Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map.
Topics: Antineoplastic Agents; Apoptosis; Benzocaine; Betazole; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Chenodeoxycholic Acid; Cytotoxins; DNA Primers; Esophageal Neoplasms; Humans; In Situ Nick-End Labeling; Metformin; MicroRNAs; Nizatidine; Organophosphates; Proline; Protein Array Analysis; Real-Time Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Transcriptome; Transfection; Tumor Suppressor Proteins | 2014 |
Rosiglitazone, medical reversal, and back to basics for diabetes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2014 |
Phosphatase and tension homolog overexpression in insulin resistant diabetic adipose tissue.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Mice; Mice, Inbred C57BL; PTEN Phosphohydrolase; Rosiglitazone; Thiazolidinediones | 2014 |
Sequential hollow-fiber liquid phase microextraction for the determination of rosiglitazone and metformin hydrochloride (anti-diabetic drugs) in biological fluids.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Liquid Phase Microextraction; Metformin; Rosiglitazone; Solvents; Thiazolidinediones | 2015 |
A toxicology study to evaluate the embryotoxicity of metformin compared with the hypoglycemic drugs, the anticancer drug, the anti-epileptic drug, the antibiotic, and the cyclo-oxygenase (COX)-2 inhibitor.
Topics: 3T3 Cells; Animals; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Agents; Cell Differentiation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Embryonic Stem Cells; Fibroblasts; Fluorouracil; Gene Expression Regulation, Developmental; Hypoglycemic Agents; Metformin; Mice; Penicillins; Phenytoin; Risk Assessment; Rosiglitazone; Sulfonamides; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
Developmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.
Topics: Androgen Antagonists; Androgens; Animals; Estrous Cycle; Female; Fetal Development; Flutamide; Hypoglycemic Agents; Luteinizing Hormone; Metformin; Polycystic Ovary Syndrome; Pregnancy; Prenatal Exposure Delayed Effects; Rosiglitazone; Sexual Maturation; Sheep; Sheep, Domestic; Testosterone; Thiazolidinediones | 2015 |
Effect of pioglitazone medication on the incidence of dementia.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Dementia; Diabetes Mellitus; Female; Germany; Humans; Hypoglycemic Agents; Incidence; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Protective Factors; Rosiglitazone; Thiazolidinediones | 2015 |
Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Antihypertensive Agents; Arteries; Cyclic GMP; Dose-Response Relationship, Drug; Drug Interactions; Glucose; Glycolysis; Hypoglycemic Agents; In Vitro Techniques; Metformin; Muscle, Smooth, Vascular; Nitric Oxide Donors; Nitroprusside; Phosphodiesterase 5 Inhibitors; Pioglitazone; Rats; Rosiglitazone; Sildenafil Citrate; Tail; Thiazolidinediones; Vasodilator Agents | 2015 |
Insulin sensitizers prevent fine particulate matter-induced vascular insulin resistance and changes in endothelial progenitor cell homeostasis.
Topics: Animals; Aorta; Ataxin-1; Caspase 1; Cells, Cultured; Diet, High-Fat; Endothelial Progenitor Cells; Homeostasis; Hypoglycemic Agents; Inflammasomes; Inflammation Mediators; Inhalation Exposure; Insulin; Insulin Resistance; Interleukin-18; Interleukin-1beta; Male; Metformin; Mice, Inbred C57BL; NF-kappa B; Oxidative Stress; Particle Size; Particulate Matter; Phosphorylation; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazolidinediones; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats.
Topics: Administration, Intravenous; Animals; Biotransformation; Canagliflozin; Chromans; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Glucuronosyltransferase; Glyburide; Hepatocytes; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Species Specificity; Substrate Specificity; Sulfotransferases; Thiazolidinediones; Troglitazone | 2016 |
Effect of Vanadyl Rosiglitazone, a New Insulin-Mimetic Vanadium Complexes, on Glucose Homeostasis of Diabetic Mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Drinking Behavior; Feeding Behavior; Homeostasis; Insulin; Male; Metformin; Mice; Quercetin; Rosiglitazone; Spectrophotometry, Infrared; Thiazolidinediones; Trehalose; Vanadium | 2016 |
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
Topics: Acarbose; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Markov Chains; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones | 2016 |
Alternatives to Metformin for Patients with PCOS.
Topics: Evidence-Based Medicine; Family Practice; Female; Humans; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; United States | 2016 |
Metformin HCl has curative effect on rebuilding of ventricular diastolic functions in high-fat-diet fed rats.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Male; Metformin; Myocardium; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Rosiglitazone; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
Topics: Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Interrupted Time Series Analysis; Legislation, Drug; Metformin; Patient Safety; Pharmacoepidemiology; Pioglitazone; Republic of Korea; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2017 |
Circulating ApoJ is closely associated with insulin resistance in human subjects.
Topics: Blood Glucose; Clusterin; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Homeostasis; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2018 |
Anti-proliferative effect of rosiglitazone in the human T-lymphocyte leukaemia cell line Jurkat cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Humans; Jurkat Cells; Leukemia, T-Cell; Metformin; PPAR gamma; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Somatomedin; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2018 |
Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study.
Topics: Abscess; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Incidence; Liver Abscess; Male; Metformin; Middle Aged; National Health Programs; Pioglitazone; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones; Treatment Outcome | 2018 |
Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome; Rosiglitazone | 2020 |
A Sensitive HPTLC Method for the Estimation of Glibenclamide, Rosiglitazone Maleate and Metformin Hydrochloride from a Multicomponent Dosage Form.
Topics: Calibration; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Glyburide; Limit of Detection; Metformin; Reproducibility of Results; Rosiglitazone; Tablets | 2020 |
Insulin inhibits inflammation-induced cone death in retinal detachment.
Topics: Adult; Animals; Cell Death; Eye Proteins; Female; Glucose; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Metformin; Mice; Mice, Inbred C57BL; Middle Aged; Retinal Cone Photoreceptor Cells; Retinal Detachment; Rosiglitazone; Thioredoxins | 2020 |
Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell populations.
Topics: Animals; Apoptosis; Blood Glucose; Cell Differentiation; Cell Proliferation; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Metformin; Mice; Rosiglitazone | 2022 |
Antidiabetic Drugs Can Reduce the Harmful Impact of Chronic Smoking on Post-Traumatic Brain Injuries.
Topics: Animals; Blood-Brain Barrier; Brain Injuries; Brain Injuries, Traumatic; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Inbred C57BL; Rosiglitazone; Tobacco Smoking | 2023 |